Where Will Major Pharmaceutical Companies Bet After GLP-1 and ADC?
After several challenging years, the biopharmaceutical industry may finally see an improvement in the deal-making environment. Integration and innovation have become key themes, and by 2025, deal activity is expected to shift significantly towards fewer but higher-value licensing deals, with mergers and acquisitions showing a similar trend. Recent major transactions, including Novo Nordisk’s acquisition of … Read more
